 This study demonstrated that LuAg09222, a humanized monoclonal antibody directed against PACAP ligand, effectively inhibited PACAP-induced catholic vasodilation and increases in heart rate and reduced concomitant headache. These results suggest that LuAg09222 could potentially be used as a therapeutic agent for migraine and other PACAP-mediated diseases. This article was offered by Nodya Bredo-Rasmussen, Christina Delagiani, Caspar Emil Christensen, and others.